Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy

Li, Sai; Liang, Tingbo; Hong, Yupeng

doi:10.1177/1533033820980116

Cited by 25 publications

(25 citation statements)

References 147 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In humans, EGFR/ErbB (the epidermal growth factor receptors), RTKs (group of receptor tyrosine kinases) comprised, ErbB2/Neu/ HER-2, EGFR/ErbB1/HER-2 & ErbB3/HER-3 [49,50]. ERBB2 is deficient in ligand binding capabilities due to its stable but enlarged ectodomain, nonetheless, it is chosen for heterodimerization on EGFR to extend the period and strength of the signals induced by the creation of high-affinity complexes with EGFR.…”

Section: Receptor Tyrosine Kinases In the Egfr/erbb Familymentioning

confidence: 99%

An in-Depth Analysis of Ovarian Cancer: Pathogenesis and Clinical Manifestation

Mahmood

Ved²,

Siddiqui

et al. 2022

Drug Res (Stuttg)

View full text Add to dashboard Cite

Ovarian cancer is characterized by the establishment of tolerance, the recurrence of disease, as well as a poor prognosis. Gene signatures in ovarian cancer cells enable cancer medicine research, therapy, prevention, & management problematic. Notwithstanding advances in tumor puncture surgery, novel combinations regimens, and abdominal radiation, which can provide outstanding reaction times, the bulk of gynecological tumor patients suffer from side effects & relapse. As a consequence, more therapy alternatives for individuals with ovarian cancer must always be studied to minimize side effects and improve progression-free and total response rates. The development of cancer medications is presently undergoing a renaissance in the quest for descriptive and prognostic ovarian cancer biomarkers. Nevertheless, abnormalities in the BRCA2 or BRCA1 genes, a variety of hereditary predispositions, unexplained onset and progression, molecular tumor diversity, and illness staging can all compromise the responsiveness and accuracy of such indicators. As a result, current ovarian cancer treatments must be supplemented with broad-spectrum & customized targeted therapeutic approaches. The objective of this review is to highlight recent contributions to the knowledge of the interrelations between selected ovarian tumor markers, various perception signs, and biochemical and molecular signaling processes, as well as one’s interpretation of much more targeted and effective treatment interventions.

show abstract

Section: Receptor Tyrosine Kinases In the Egfr/erbb Familymentioning

confidence: 99%

An in-Depth Analysis of Ovarian Cancer: Pathogenesis and Clinical Manifestation

Mahmood

Ved²,

Siddiqui

et al. 2022

Drug Res (Stuttg)

View full text Add to dashboard Cite

show abstract

“… 106 Over the past decade, compelling research has shown that the judicious use of anti-angiogenic therapies can temporarily normalize tumor vasculature and increase drug and anti-tumor immune cell delivery while alleviating hypoxia in the TME, thereby increasing the effectiveness of various treatments. 107 Tumor vascular normalization has been shown to improve the efficacy of cancer immunotherapy, and recent studies have shown that enhanced immune stimulation can in turn improve tumor vascular normalization. 108 Interferon γ is produced by activated T cells and induces T-cell migration; it plays an important role in this process.…”

Section: Biological Rationale For the Anti-angiogenic-immunotherapy C...mentioning

confidence: 99%

“…Feedback between ICB and anti-angiogenic enhances itself and ultimately drives immune-mediated tumor cell eradication. 107 …”

Section: Biological Rationale For the Anti-angiogenic-immunotherapy C...mentioning

confidence: 99%

“… 55 A clinical trial of patients with advanced GC/GEJC evaluating the efficacy of ramucirumab plus pembrolizumab combination showed encouraging clinical activity and manageable toxicity. 107 In the REGONIVO study, the combination of regorafenib and nivolumab showed remarkable anti-tumor activity (ORR = 44%) in patients with GC who had shown a poor response to prior therapy. This indicates that adding an anti-angiogenic monoclonal antibody or TKI to immunotherapy could be another treatment option for advanced GC.…”

Section: Clinical Evidence For Combination Of Anti-angiogenic Therapy...mentioning

confidence: 99%

See 1 more Smart Citation

Tumor vessel normalization and immunotherapy in gastric cancer

Shen

et al. 2022

Ther Adv Med Oncol

View full text Add to dashboard Cite

Gastric cancer (GC) is a common malignant tumor, and patients with GC have a low survival rate due to limited effective treatment methods. Angiogenesis and immune evasion are two key processes in GC progression, and they act synergistically to promote tumor progression. Tumor vascular normalization has been shown to improve the efficacy of cancer immunotherapy, which in turn may be improved through enhanced immune stimulation. Therefore, it may be interesting to identify synergies between immunomodulatory agents and anti-angiogenic therapies in GC. This strategy aims to normalize the tumor microenvironment through the action of the anti-vascular endothelial growth factor while stimulating the immune response through immunotherapy and prolonging the survival of GC patients.

show abstract

“…New angiogenesis actually plays a key role in tumor development, invasion, and metastases formation of many cancers, including NMSC [ 18 , 19 ]. Vascular Endothelial Growth Factor (VEGF) family is considered to be a fundamental key factor involved in angiogenesis, influencing progression, prognosis and therapy in various forms of cancers [ 20 , 21 , 22 , 23 , 24 , 25 , 26 ]. Specific variations of VEGF genes have been demonstrated to be genetic determinants for susceptibility, outcome and therapy response, especially for the solid tumors.…”

Section: Introductionmentioning

confidence: 99%

TGF-β/VEGF-A Genetic Variants Interplay in Genetic Susceptibility to Non-Melanocytic Skin Cancer

Scola

Bongiorno

Forte

et al. 2022

Genes

View full text Add to dashboard Cite

Differential genetically determined expression of transforming growth factor-β (TGF-β pathway and of vascular endothelial growth factor-A (VEGF-A) might modulate the molecular “milieu” involved in the etio-pathogenesis of non-melanoma skin cancer (NMSC). We have evaluated the frequency of some functionally relevant SNPs of TGF-β and VEGF-A genes in 70 NMSC patients and 161 healthy controls, typed for TGF-β1 rs1800471, TGF-β2 rs900, TGF-βR1 rs334348 and rs334349, TGF-βR2 rs4522809 and VEGF-A rs3025039 SNPs. TGF-βR2 rs1800629G allele and related genotypes were found to be associated with a possible protective role against NMSC, whereas VEGF-A rs3025039T was associated with an increased risk. To evaluate the effect of genotype combinations on NMSC susceptibility, we determined the frequencies of 31 pseudo-haplotypes due to non-random linkage among alleles of loci not lying on the same chromosome. Two pseudo-haplotypes that imply a minor allele of TGF-βR2 or minor allele of VEGF-A SNPs combined with major alleles of the other SNPs were, respectively, associated with a protective effect, and susceptibility to NMSC. In addition, a pseudo-haplotype involving minor alleles of TGF-β2 rs900, TGF-βR1 rs334348 and rs4522809 SNPs might be a susceptibility marker for NMSC. In conclusion, our data suggest that a complex interplay among the genetic polymorphisms of TGF-β, TGF-β receptors and VEGF-A genes might influence the net effect of genetic background of the patients on NMSC development. This might be relevant in the risk evaluation, diagnosis and treatment of NMSC.

show abstract

Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy

Cited by 25 publications

References 147 publications

An in-Depth Analysis of Ovarian Cancer: Pathogenesis and Clinical Manifestation

An in-Depth Analysis of Ovarian Cancer: Pathogenesis and Clinical Manifestation

Tumor vessel normalization and immunotherapy in gastric cancer

TGF-β/VEGF-A Genetic Variants Interplay in Genetic Susceptibility to Non-Melanocytic Skin Cancer

Contact Info

Product

Resources

About